Rhinomed Ltd (RNO.AX) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Rhinomed Ltd's Turbine granted US FDA registration


Wednesday, 16 Jul 2014 08:00pm EDT 

Rhinomed Ltd:Says that it has granted registeration with US FDA as a medical device.The Turbine is an internal nasal dilator that increases airflow by an average of 38 pct. and can assist athletes as a valuable to solution to dyspnea (breathlessness) during aerobic exercise. 

Company Quote

0.019
-0.0010 -5.00%
30 Jun 2016